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Abstract: There is an ongoing need for development of new chemotherapeutic regimens for metastatic breast cancer [mBC], especially 
when tumors lack therapeutic targets such as the estrogen or progesterone receptor [ER/PR], or the human epidermal growth factor 
receptor-2 [HER2].  Capecitabine is an orally bioavailable fluoropyrimidine approved for monotherapy in mBC, and bevacizumab is a 
monoclonal antibody targeting vascular endothelial growth factor which has shown to be active in mBC and tolerable in combination 
with other chemotherapeutics.  The combination of these two agents has been explored in multiple phase II and III clinical studies, with 
improvements in progression-free survival and overall response rates noted as compared to capecitabine monotherapy.  However, the 
use of bevacizumab in combination with capecitabine and other chemotherapy agents for mBC remains beset with controversy due to 
safety concerns, cost issues, and pending regulatory decisions.
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Introduction
Despite  many  recent  advances  in  the  therapy  of 
  metastatic breast cancer [mBC], the median survival 
of  newly  diagnosed  patients  remains  at  approxi-
mately 2 years.1 Many of these advances have been 
achieved through the development of targeted thera-
pies. The initial targeted therapies for breast cancer 
were endocrine-based therapies (ie, tamoxifen and 
subsequently the aromatase inhibitors), which sup-
press  hormone-mediated  growth  signals  to  tumor 
cells  that  express  estrogen  and/or  progesterone 
receptors [ER/PR].2,3 More recently, the identifica-
tion of a subset of breast cancers that overexpress 
the  human  epidermal  growth  factor  receptor-2 
[HER2], and subsequent development of the mono-
clonal antibody trastuzumab that targets the recep-
tor, has resulted in meaningful gains in survival in 
patients with these tumors.4 However, a significant 
proportion of patients are still diagnosed with breast 
cancers that either do not express one of these three 
therapeutic targets, such as the so-called “triple-neg-
ative” breast cancers [TNBC]; or tumors which have 
lost the ability to respond to the targeted agents, such 
as the endocrine resistant tumors. A new target that 
has been identified in the last few years is the vas-
cular endothelial growth factor [VEGF], which is a 
key mediator for tumor growth by promoting angio-
genesis and   neovascularization.   Blocking the VEGF 
ligand selectively has been shown to inhibit tumor 
angiogenesis  and  cell  proliferation.5  In    addition, 
some  investigators  have  suggested  that  inhibiting 
VEGF activity allows increased penetration of tra-
ditional cytotoxic agents into tumor   tissue, enhanc-
ing the antitumor effect of these agents.6 Therefore, 
utilizing combinations of VEGF targeted agents and 
traditional  chemotherapy  is  an  attractive  option. 
In this work we will review the role of the bevaci-
zumab-capecitabine combination as first-line treat-
ment of metastatic breast cancer.
Bevacizumab and Capecitabine  
Bevacizumab
There  are  a  number  of  investigational  antiangio-
genic agents for the treatment of advanced or mBC.7 
  Bevacizumab is a fully human monoclonal antibody 
against soluble VEGF-A which was initially approved 
by the United States Food and Drug Administration in 
2004 for the treatment of metastatic colorectal   cancer 
in combination with 5-FU based-  chemotherapy.8 It 
is  currently  approved  for  the  treatment  of  several 
malignant  disorders  such  as  breast,  colon,  renal, 
brain (glioblastomas) and non-squamous non-small 
cell  lung  cancers,  but  is  also  being  used  in  non-
  malignant conditions, such as ocular disorders due 
to neovascularization. Its use in mBC has been an 
area  of  active  investigation  for  several  years,  ini-
tially as a single agent9 and more recently as a part 
of multiple iterations of combination regimens.10–12 
In the landmark ECOG 2100 trial, adding bevaci-
zumab to weekly paclitaxel, significantly prolonged 
median progression-free survival (PFS, 11.8 months 
versus 5.9 months; P , 0.0001) and almost doubled 
the  objective  response  rate  (ORR)  (36.9%  versus 
21.2%; P , 0.001) over paclitaxel alone in previ-
ously  untreated  mBC.10  However,  overall  survival 
was not improved.
Capecitabine
5-fluorouracil  [5-FU]  has  long  been  incorporated 
into  chemotherapy  regimens  both  for  adjuvant 
and metastatic disease, but its use has been com-
plicated  by  adverse  effects  and  difficulty  with 
  administration.13  In  the  past  decade,  capecitabine, 
an oral fluoropyrimidine which is selectively con-
verted to 5-FU in tumor cells,14 has been studied 
in  multiple  tumor  types,  including  breast  cancer. 
Its ease of administration, relatively favorable tox-
icity profile, and lack of cross-resistance to other 
commonly  used  chemotherapeutic  agents  make  it 
an attractive treatment option for metastatic breast 
cancer. Capecitabine was first explored in metastatic 
breast cancer by Blum et al in a phase II study in 
patients previously treated with two or three chemo-
therapy regimens.15 162 patients were treated with 
capecitabine 2500 mg/m2/day in divided doses, with 
27 (20%) complete or partial responses, and another 
54 patients (40%) with stable disease. Median time 
to  progression  was  approximately  3  months,  and 
median survival was 12.8 months. As a result of this 
study, capecitabine was the first drug to be approved 
for use in metastatic breast cancer patients who were 
resistant to paclitaxel/  anthracycline-containing regi-
mens or resistant to paclitaxel and not a candidate for 
further anthracycline therapy. It was also approved Capecitabine with Bevacizumab in Metastatic Breast Cancer
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in    combination  with  docetaxel  for  the  treatment 
of  mBC  that  has  failed  prior  anthracycline-based 
therapy.16
Clinical studies of the combination  
of capecitabine plus bevacizumab  
in breast cancer
Several clinical trials have explored the use of capecit-
abine  in  combination  with  bevacizumab,  and  are 
summarized in Table 1. As is common with the devel-
opment of most agents in oncology, the combination 
of capecitabine and bevacizumab (CAPE + BEV) was 
initially studied in previously treated patients with 
mBC (second/third line therapy). The seminal trial in 
this setting was the avf2119 g study.17 This study ran-
domized 462 patients to capecitabine 2500 mg/m2 in 
two divided daily doses for two weeks followed by a 
week off, or the same dose and schedule of capecit-
abine plus bevacizumab 15 mg/kg every three weeks. 
Although an improvement in overall response rate 
was seen with the addition of bevacizumab (19.8% 
vs.  9.1%),  it  did  not  meet  the  primary  end-point 
of improvement of PFS (4.17 vs. 4.86 months for 
CAPE vs. CAPE-BEV respectively; P = 0.857) and 
the OS was also the same in the two groups (14.5 vs. 
15.1 months; P = 0.63). The authors felt that the addi-
tion of antiangiogenic therapy earlier in the course of 
disease was more likely to have clinical benefit.
The  first  study  to  evaluate  the  combination  of 
capecitabine and bevacizumab (CAPE + BEV) in the 
first-line setting was the multi-center phase II study 
XCALIBr, initially reported at the 2007 annual meet-
ing of the American Society of Clinical   Oncology 
(ASCO).18 The primary end-point was to evaluate time 
to progression (TTP) in chemotherapy-naive HER2 
negative metastatic breast cancer patients.   Secondary 
endpoints included overall survival, overall response 
rate, response duration, biomarkers, quality of life, 
time-to-failure  and  safety  profile.  One  hundred 
and  three  patients  were  treated  with  capecitabine 
1000 mg/m2 twice a day for 14 days with seven days 
off in combination with bevacizumab at 15 mg/kg IV 
in three-week cycles until first progression or intoler-
ance to treatment. Once progression was documented, 
patients  were  treated  with  second-line  therapy  of 
BEV in combination with either weekly paclitaxel or 
vinorelbine. The ORR was 38.5% (with an additional 
42.9% achieving stable disease). Median PFS was 
5.7 months (95% CI 4.9–8.4 months), with a median 
overall survival of 16 months. Women with advanced 
estrogen receptor positive breast cancer demonstrated 
an especially significant delay in disease progression, 
with a median delay of 8.9 months. The most com-
mon grade 3 adverse events were hand-foot syndrome 
(13%) and pain (10%). The most serious AE was pul-
monary embolism (2%).
The  above  study  supported  the  development  of 
a larger phase III study evaluating the use of beva-
cizumab and capecitabine as first line treatment for 
mBC. The  RIBBON-1  study  was  an  international, 
  multicenter,  double-blinded,  placebo-controlled, 
phase III trial designed to look at the addition of beva-
cizumab to multiple chemotherapeutic agents in 1,237 
patients who did not receive previous chemotherapy 
for their HER2-negative locally recurrent or metastatic 
breast cancer. It was initially presented at the annual 
ASCO meeting in 2009 and recently   published.12 The 
chemotherapy  backbone  was  preselected  for  each 
patient at the treating physician’s and patient’s dis-
cretion, and subsequently patients were randomized 
to chemotherapy plus placebo or chemotherapy plus 
  bevacizumab. Patients were randomized in a 2:1 ratio 
to receive bevacizumab plus   chemotherapy. One of the 
chemotherapy options was capecitabine (as opposed 
Table 1. Key mBC trials utilizing the capecitabine-bevacizumab combination.
Study Setting Design n Median PFS  
(mos.)
ORR Median OS  
(mos.)
Avf2119 Previously treated Phase ii, randomized 232 4.86 19.8% 15.1 mo.
XCALiBr Newly diagnosed Phase ii, single arm 103 5.7 38.5% 16.0 mo.
RiBBON-1 Newly diagnosed Phase iii 409 8.9 35.4% Not reached
ATHeNA Newly diagnosed Open-label, observational 102 7.0* 36.3% Not reached
Note: *reported as “time to progression”.
Abbreviations: PFS, progression-free survival; OS, overall survival; mos., months.Dyar and Moreno-Aspitia
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to the other option of taxane- or anthracycline-based 
chemotherapy).  In  all,  capecitabine  was  selected 
for 615 patients, 409 of whom were randomized to 
capecitabine plus bevacizumab [CAPE + BEV], and 
206 of whom were randomized to capecitabine plus 
placebo [CAPE]. Capecitabine dose was 1000 mg/m2 
twice daily for 14 days followed by 7 days off, while 
bevacizumab was given 15 mg/kg every three weeks. 
The two groups were evenly matched with respect to 
baseline characteristics.
The  primary  endpoint  of  the  RIBBON-1  study 
was progression free survival, with overall response 
rate, overall survival, 1 year survival, and duration 
of response listed as secondary endpoints. Median 
progression free survival was significantly longer in 
the CAPE + BEV group, 8.9 months as opposed to 
5.7 months in the CAPE group (HR 0.69 (0.52–0.80); 
P  ,  0.001).  Kaplan  Meier  curves  demonstrated  a 
separation in the PFS curves at about 3 months, with 
convergence  of  the  curves  seen  at  approximately 
18  months,  suggesting  some  possible  dilution  of 
therapeutic effect due to crossover and second-line 
therapies.  Overall  response  rate  was  significantly 
higher in the CAPE + BEV group (35.4% vs. 23.6%, 
P = 0.0097), but there was no statistically significant 
overall survival difference or in the 1-year survival 
rate. Taken with similar results seen for the taxane 
and anthracycline cohorts, the authors of the study 
concluded that the study provides rationale for add-
ing bevacizumab to chemotherapy.
In addition to the above randomized trial looking 
at capecitabine and bevacizumab, there was a large 
single-arm, open label study of bevacizumab in com-
bination with chemotherapy in the first-line setting, 
known as ATHENA, which primarily sought to exam-
ine safety endpoints in a setting that was thought to 
better represent a “real-world” scenario.19 The vast 
majority of the 2251 patients in this study received 
a taxane-based therapy, but 102, or 4.5% of patients, 
received  capecitabine  as  a  chemotherapy  back-
bone, and subgroup analyses for each regimen were 
reported for efficacy and safety endpoints. Median 
time to progression for CAPE + BEV was 7.0 months 
(95% CI 5.8–8.6), slightly lower than that observed 
in the RIBBON-1 study, but the overall response rate 
of 36.3% was fairly comparable. Additionally, 42.0% 
of patients achieved stabilization of their disease. No 
new safety signals for bevacizumab were observed in 
the study. Grade $ 3 hypertension was seen in 4.4% 
of patients and grade $ 3 bleeding occurred in 1.4% 
of patients.
Attempts have also been made to build on the effi-
cacy of capecitabine and bevacizumab combination. 
A small phase II study by the North Central Cancer 
treatment Group (NCCTG), the N0432 trial, looked 
at the use of docetaxel in combination with capecit-
abine and bevacizumab in the first line mBC   setting.20 
45 patients were enrolled, and efficacy results were 
encouraging  with  a  49%  ORR  and  median  PFS 
11.1 months. However, despite reducing the start-
ing dose of capecitabine to 825 mg/m2 BID, 98% of 
patients had at least one grade 3 or 4 adverse event, 
resulting  in  multiple  dose  reductions  and  delays. 
Hematologic toxicities were common including 78% 
of patients with grade 3 or 4 neutropenia.
The use of the combination of bevacizumab and 
capecitabine is an area of ongoing research interest, 
and there are currently several pending clinical trials 
which are awaiting results or completion of accrual. 
The TURANDOT trial from the Central   European 
Cooperative  Oncology  Group  is  a  randomized 
phase III trial comparing capecitabine and bevaci-
zumab to paclitaxel and bevacizumab in the first line 
mBC setting. It is currently closed after completing 
accrual.21 Safety data was reported for 80 patients in 
the CAPE + BEV arm (174 patients total enrolled) at 
the ASCO 2010 annual meeting; efficacy data has not 
yet been reported.22 The CARIN trial from   Germany 
has  completed  randomization  of  400  patients  to 
CAPE  +  BEV  or  CAPE  +  BEV  +    vinorelbine. 
  Preliminary safety data was reported at the ASCO 
2011  annual  meeting;  efficacy  data  has  yet  to  be 
published.23 The South Eastern European Research 
Oncology Group is also currently recruiting partici-
pants for a single-arm phase II study of capecitabine 
and bevacizumab as first line therapy in women over 
the age of 70 with mBC.24
Safety of the combination of capecitabine 
plus bevacizumab in breast cancer
Of course, despite positive efficacy results in phase II 
and III clinical trials, the safety of the addition of 
bevacizumab to capecitabine is of the utmost con-
cern.  The  adverse  event  (AE)  profiles  of  the  two 
drugs  have  been  well  described  as  monotherapy, 
with  capecitabine  most  notably  causing  hand-foot Capecitabine with Bevacizumab in Metastatic Breast Cancer
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  syndrome, myelosuppression and GI adverse events 
such as diarrhea,15 and bevacizumab causing hyper-
tension,  proteinuria,  bleeding  and  thromboembolic 
events.8,9 Fortunately, there is little overlap between 
these two toxicity profiles, but nevertheless, it has 
been  important  to  ensure  that  the  AEs  seen  with 
monotherapies are not potentiated by the two-drug 
combination. Taken as a whole, there is now a moder-
ate amount of safety data available for the evaluation 
of the   capecitabine-bevacizumab regimen in MBC, 
which is summarized in Table 2.
Early studies utilizing the CAPE + BEV regimen 
provided initial reassurance that the two drugs, when 
combined, were tolerable for patients. The avf2119-
study from Miller et al17 reported that capecitabine tox-
icities were similar with or without   bevacizumab—for 
example, rates of grade 3 hand-foot syndrome were 
24.2%  for  monotherapy  vs.  27.5%  for  the  combi-
nation regimen, and rates of grade 3 diarrhea were 
10.7%  for  monotherapy  vs.  11.8%  for  combina-
tion  therapy.  Dose  reductions  were  very  common 
in both groups, 65% in the CAPE group and 79% in 
the CAPE + BEV group (the starting dose of capecit-
abine was 2500 mg/m2 cumulative daily dose, which 
was  subsequently  lowered  in  later  studies).  Rates 
of    therapy  discontinuation  were  virtually  identical 
between the groups. Hypertension and minor mucosal 
bleeding was  more  common  in  the  CAPE  + BEV 
group,  but  rates  of  thromboembolic  events  were 
infrequent. Seven patients on the CAPE + BEV arm 
developed grade 3 or 4 congestive heart failure or car-
diomyopathy, against only 2 patients on capecitabine 
alone. However, it warrants mention that all patients 
on both arms were pretreated with anthracyclines.
The RIBBON-1 trial provided the largest data set 
for  safety  analysis  in  the  combination  regimen  of 
bevacizumab and capecitabine.12 Overall, there were 
higher rates of AEs reported in the combination arms 
than in the arms containing chemotherapy   without 
bevacizumab.  Specifically  for  the    combination  of 
bevacizumab  and  capecitabine,  hypertension  and 
proteinuria  were  increased,  as  expected.  Venous 
thromboembolism  was  noted  in  20  out  of  404 
patients (5.0%) in the combination arm, and 7 out of 
201  patients  (3.5%)  on  capecitabine  monotherapy. 
There were also trends noted toward higher incidence 
of sensory neuropathy (12 patients on CAPE + BEV, 
1 patient on CAPE alone), as well as left ventricular 
dysfunction (6 patients on CAPE + BEV, 1 patient 
on  CAPE  alone);  however,  statistical  significance 
was not reported for the safety analyses within this 
subgroup. Fatal AEs were low in both groups, 5 on 
capecitabine alone and 6 on the combination arm. An 
equal number of patients in both arms, 11.9%, had 
an AE leading to drug discontinuation. The authors 
concluded that the addition of bevacizumab to che-
motherapy did not significantly alter the toxicities of 
these agents or result in an increased number of fatal 
toxicities.
Because  of  the  small  signal  of  left  ventricular 
dysfunction noted in these and other trials, a meta-
  analysis  was  undertaken  to  examine  the  incidence 
of  CHF  in  patients  treated  with  bevacizumab  for 
mBC.25 The study included 5 large randomized trials, 
including  avf2119  g,  RIBBON-1  and  RIBBON-2, 
among others. The study demonstrated a significantly 
increased risk of congestive heart failure in patients 
treated with bevacizumab (1.6% vs. 0.4%, RR 4.74, 
P = 0.001). Important caveats include the fact that 
the extent of the interaction with other therapies such 
as anthracyclines is unknown, and the absolute inci-
dence is small, less than 2%.
The  ATHENA  study  reported  safety  analyses 
for the 102 patients in the capecitabine subgroup.19 
45.1% had at least 1 grade 3 or higher AE, with 21.6% 
of  patients  having  a  serious  event. Absolute  num-
bers of specific grade 3 AEs were small, including 
5.9% hypertension, 1.0% proteinuria, 4.9% arterial 
Table 2. Key safety endpoints for published capecitabine-bevacizumab trials in percentage of patients.




Proteinuria GI perforation CHF
Avf2119* 229 23.6 (17.9) 7.4 (5.7) 69.9 (27.5) 22.3 (0.9) Not reported 2.2 (2.2)
RiBBON-1† 404 10.1 5.0 Not reported 2.2 0 1.5
ATHeNA‡ 102 5.9 4.9 Not reported 1.0 0 0
Notes: *All Aes (grade 3 and 4 Aes in parentheses). †Grade 2 and above Aes. ‡Grade 3 and above Aes.
Abbreviation: CHF, congestive heart failure.Dyar and Moreno-Aspitia
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or venous thromboembolism, and 1% hemorrhage. 
No patients with grade 3 CHF were reported in the 
capecitabine subgroup.
Interim safety analyses have been reported in some 
ongoing trials as well. The TURANDOT study has not 
yet reported efficacy results, but preliminary safety 
data  has  been  performed.22  Eighty  patients  receiv-
ing CAPE + BEV were evaluated at a pre-specified 
interim analysis: 80% of patients had at least one AE; 
31% had grade 3 AEs, with 10% of patients experi-
encing a serious AE. The most common grade 3 or 
4 AE reported was diarrhea, at a frequency of 8.8%. 
The CARIN trial comparing CAPE + BEV with or 
without vinorelbine also has reported interim safety 
data,23 with grade 3 hypertension or thromboembolic 
events reported uncommonly (1 patient in each arm). 
Neutropenia was frequently seen, but almost exclu-
sively in the vinorelbine group.
Although the dosing of capecitabine 1000 mg/m2 
BID for 14 days of a 21 day cycle has been used most 
commonly,  several  different  dosing  schedules  have 
been employed in an attempt to find the most effi-
cacious  schedule  while  minimizing  toxicity.  Gajria 
et  al  from  the  Memorial  Sloan  Kettering  Cancer 
  Center reported a single arm, phase II trial26 that used 
a flat capecitabine dose of 2000 mg BID for 7 days, 
followed  by  7  days  off,  along  with  bevacizumab 
10 mg/kg every two weeks. Prior chemotherapy was 
allowed,  and  a  total  of  41  patients  were  enrolled. 
Efficacy data was similar to other reported studies of 
capecitabine plus bevacizumab, with median PFS of 
about 8 months, ORR of 20% and 35% stable   disease. 
However, dose reduction or delay of capecitabine was 
still needed in 32 of 41 patients (78%), with 9 patients 
discontinuing study medication due to adverse effects. 
  Gastrointestinal side effects were lessened, but hand-
foot syndrome was still present in numbers similar 
to other schedules of capecitabine and bevacizumab. 
Seven patients required dose reduction of bevacizumab 
due to hypertension, and 2 patients had a thromboem-
bolic event. No patients died while on study.
In summary, although there is a discernible increase 
in  toxicities  with  the  addition  of  bevacizumab  to 
capecitabine,  the  toxicities  are  generally  tolerable. 
Serious  adverse  events  include  thromboembolism 
and  congestive  heart  failure,  although  fortunately 
these are quite uncommon.
Place in Therapy
Despite a growing body of evidence with the use of 
these agents, efficacy and safety results do not tell 
the complete story with bevacizumab as combina-
tion  therapy.  Perhaps  no  other  oncologic  drug  in 
recent memory has caused as much controversy as 
  bevacizumab.  In  July  2010,  the  Oncologic  Drugs 
Advisory Committee (ODAC) of the United States 
Food and Drug Administration (FDA) voted 12-1 to 
recommend withdrawal of the conditional approval 
of bevacizumab as front-line therapy for HER2 neg-
ative mBC based on their concerns of the potential 
serious adverse events with this agent, the lack of 
confirmation of the magnitude of benefit seen in the 
E2100 trial (comparing paclitaxel with and without 
bevacizumab10) in the RIBBON-1 trial, as well as the 
AVADO trial, another seminal trial examining doc-
etaxel with or without bevacizumab11 and the lack 
of improvement in OS in all those trials. On Decem-
ber 15, 2010, the FDA’s Center for Drug Evaluation 
and Research recommended to initiate the process of 
withdrawal of the approval of the breast cancer indi-
cation  for  bevacizumab.27  Subsequently,  Europe’s 
regulatory  body,  the  European  Medicine  Agency, 
released a statement that bevacizumab would remain 
as an option for metastatic breast cancer, but only 
when used in combination with paclitaxel.28 On June 
27th–28th, 2011, the FDA conducted a hearing with 
the Center for Drug Evaluation and Research and 
the manufacturer of bevacizumab, Genentech, which 
further  explored  the  approval  of  bevacizumab  for 
treatment  of  metastatic  breast  cancer.29  Following 
this meeting the Centers for Medicare &   Medicaid 
Services made a public statement that they will con-
tinue to pay for bevacizumab when it’s used to treat 
metastatic breast cancer, even if the FDA decides 
to remove that indication from the drug.30 Also the 
National Comprehensive Cancer Network (NCCN), 
has voted overwhelmingly in favor of maintaining its 
recommendation that bevacizumab should continue 
to be available as an option to treat mBC.31 A final 
ruling from Dr. Margaret Hamburg, commissioner of 
the FDA, was still pending at the time of submis-
sion of this manuscript. Although bevacizumab is in 
no danger of removal from the market because of its 
current indications in other tumor types, the removal 
of the breast cancer indication from the labeling of Capecitabine with Bevacizumab in Metastatic Breast Cancer
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bevacizumab would likely result in decreased ability 
of researchers and providers to use this medication 
in mBC.
It  is  also  impossible  to  have  a  meaningful  dis-
cussion regarding the use of bevacizumab in breast 
cancer  without  mentioning  the  concerns  over  cost 
of  therapy. A  study  from  Switzerland  utilized  the 
data from the avf2119, E2100, and AVADO studies 
to  determine  the  cost-effectiveness  of  the  addition 
of bevacizumab therapy in MBC.32 The conclusion 
of  this  study,  conducted  under  the  constraints  of 
the Swiss health system, was that addition of beva-
cizumab to weekly paclitaxel was estimated to cost 
40,369 euros (approximately $58,000 US dollars) for 
the gain of 0.22 quality adjusted life years, equaling 
an  incremental  cost-effectiveness  ratio  of  189,427 
euros ($272,812 USD) per QALY gained. Of course, 
the improvement in survival needed to justify the use 
of a particular agent is subjective, but the authors 
point out that bevacizumab is expensive compared to 
common willingness-to-pay thresholds.
Conclusions
At this time, there remain many unanswered questions 
regarding the use of capecitabine and bevacizumab 
in the first line setting for metastatic breast cancer. 
Based on the results from well conducted large clini-
cal    trials,  taxanes  and  anthracyclines  are  likely  to 
remain the standard first line therapy for patients who 
are able to tolerate and willing to receive these agents. 
However, the relatively favorable toxicity profile and 
the ease of orally administered therapy make capecit-
abine an attractive option for patients and providers. 
The additive benefits of bevacizumab, however, do 
seem to extend not only to taxanes but also to capecit-
abine therapy, and for patients with contraindications 
to taxane-based therapy, combination treatment with 
these two agents is relatively safe and tolerable.
Perhaps the most important question remaining is, 
“How much benefit is enough?” The benchmark of 
overall survival has been difficult to achieve by these 
large trials, hypothetically because of the availability 
of several additional therapies that can prolong survival 
and dilute the therapeutic effect of the study agents 
after they are discontinued33 and possibly also because 
the aforementioned trials were not powered enough 
to demonstrate statistically significant improvement 
in overall survival. Therefore, the use of progression 
free survival as a meaningful surrogate has dramatic 
implications for the use of drugs like bevacizumab. 
The RIBBON-1, E2100 and AVADO trials all demon-
strated an advantage for PFS when bevacizumab was 
added  to  chemotherapy;  although  these  differences 
were  statistically  significant,  were  they  clinically 
  significant? The answer may vary between providers, 
payors, and regulatory bodies, creating an undercur-
rent of tension that is not easily resolved.
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